Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Pre‐analytical sample handling might affect the results of Alzheimer's disease blood‐based biomarkers. We empirically tested variations of common blood collection and handling procedures.

[1]  D. Holtzman,et al.  A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis , 2021, Molecular Neurodegeneration.

[2]  W. M. van der Flier,et al.  Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. , 2021, The Lancet. Healthy longevity.

[3]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2021, Translational Psychiatry.

[4]  K. Blennow,et al.  Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions , 2021, Alzheimer's & dementia.

[5]  K. Blennow,et al.  Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration , 2021, Alzheimer's & dementia.

[6]  H. Vanderstichele,et al.  Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis , 2020, Alzheimer's Research & Therapy.

[7]  H. Zetterberg,et al.  Serum neurofilament light chain withstands delayed freezing and repeated thawing , 2020, Scientific Reports.

[8]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[9]  P. Scheltens,et al.  Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease , 2020, Scientific Reports.

[10]  Patrick J. Lao,et al.  Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study , 2020, medRxiv.

[11]  J. Weuve,et al.  Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study , 2020, Annals of neurology.

[12]  Pei-Ning Wang,et al.  Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia , 2020, Dementia and Geriatric Cognitive Disorders.

[13]  Erin E. Chambers,et al.  First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[14]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[15]  J. Wiltfang,et al.  Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood. , 2020, Journal of Alzheimer's disease : JAD.

[16]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[17]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[18]  K. Blennow,et al.  Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF , 2020, Alzheimer's & dementia.

[19]  J. Trojanowski,et al.  Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays , 2019, Scientific Reports.

[20]  R. Batrla,et al.  Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers , 2019, Alzheimer's & dementia.

[21]  K. Blennow,et al.  Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[22]  J. Kassubek,et al.  Serum GFAP as a biomarker for disease severity in multiple sclerosis , 2018, Scientific Reports.

[23]  W. M. van der Flier,et al.  Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project , 2018, Alzheimer's & Dementia.

[24]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[25]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[26]  K. Blennow,et al.  Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[27]  A. Fagan,et al.  The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review , 2018, Alzheimer's & Dementia.

[28]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[29]  Young Ho Park,et al.  Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42 , 2017, Alzheimer's Research & Therapy.

[30]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[31]  H. Vanderstichele,et al.  How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio , 2017, Alzheimer's & Dementia.

[32]  Henrik Zetterberg,et al.  Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease , 2017, JAMA neurology.

[33]  Philip S. Insel,et al.  Plasma tau in Alzheimer disease , 2016, Neurology.

[34]  V. Pérez-Grijalba,et al.  Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma , 2016, Journal of Alzheimer's disease : JAD.

[35]  Tormod Fladby,et al.  A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..

[36]  A. Fagan,et al.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.

[37]  Philip Scheltens,et al.  Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice , 2014, PloS one.

[38]  M. Carrillo,et al.  CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.

[39]  J. Molinuevo,et al.  Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.

[40]  Pedro Pesini,et al.  Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD , 2012, International journal of Alzheimer's disease.

[41]  E. Siemers,et al.  The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma β-amyloid isoforms using the INNO-BIA plasma Aβ forms multiplex assay , 2009, The journal of nutrition, health & aging.

[42]  P. Lewczuk,et al.  Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. , 2019, Journal of Alzheimer's disease : JAD.

[43]  C. Rowe,et al.  High performance plasma amyloid-beta biomarkers for Alzheimer's disease , 2018 .